Galectin Therapeutics (NASDAQ:GALT) rose 11.43% on June 23, 2026, as an FDA agreement cleared a path for a Phase 3 MASH trial, with shares closing at $3.12.

Key Highlights

  • Rose 11.43%: Galectin Therapeutics closed at $3.12 on June 23 after moving $0.32 per share.
  • Catalyst: During the session, an FDA agreement cleared a path for a Phase 3 MASH trial.
  • Company: Galectin Therapeutics develops belapectin for patients with MASH cirrhosis and portal hypertension.
  • Session: The stock finished at $3.12, while the available company record showed a disclosed catalyst for the move.

Galectin Therapeutics (NASDAQ:GALT) rose 11.43% on June 23, 2026, closing at $3.12 after a $0.32 per-share move. The session’s advance came as an FDA agreement cleared a path for a Phase 3 MASH trial, based on the available company disclosures and trading context.

Galectin Therapeutics reported positive feedback from an in-person Type C meeting with the FDA, securing agreement on the primary endpoint, trial design, and regulatory pathway for a Phase 3 study of belapectin in patients with MASH cirrhosis and portal hypertension. The planned randomized, double-blind, placebo-controlled trial will evaluate a single 2 mg dose of belapectin to prevent development of esophageal varices, with Galectin planning to submit the final protocol to the FDA in Q3 2026.

Galectin Therapeutics develops belapectin for patients with MASH cirrhosis and portal hypertension.

The FDA confirmed a traditional full-approval pathway based on a single adequate, well-controlled study, materially de-risking the regulatory path. Galectin is actively seeking strategic and financial partners to fund the Phase 3 programme.

The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.

The shares closed at $3.12 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.

For the June 23 close, the defining facts were the 11.43% advance, the $3.12 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.